ProCE Banner Activity

Lenalidomide Now Approved for Maintenance in Myeloma

Clinical Thought
Lenalidomide is now the first agent approved as maintenance therapy in myeloma after ASCT, but questions remain regarding its optimal use and identification of patients who will benefit the most.

Released: April 25, 2017

Expiration: April 24, 2018

No longer available for credit.

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Oncology

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celgene, Janssen, Merck, Millennium, Novartis, and Onyx and funds for research support from Bristol-Myers Squibb, Celgene, Janssen, Millennium, and Novartis.